263 related articles for article (PubMed ID: 35550867)
41. Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
Rivière E; Verboven L; Dippenaar A; Goossens S; De Vos E; Streicher E; Cuypers B; Laukens K; Ben-Rached F; Rodwell TC; Pain A; Warren RM; Heupink TH; Van Rie A
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0032222. PubMed ID: 35758754
[TBL] [Abstract][Full Text] [Related]
42. Clofazimine Exposure
Ismail N; Peters RPH; Ismail NA; Omar SV
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
[TBL] [Abstract][Full Text] [Related]
43.
Ismail N; Ismail NA; Omar SV; Peters RPH
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138569
[TBL] [Abstract][Full Text] [Related]
44. Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.
Brown TS; Tang L; Omar SV; Joseph L; Meintjes G; Maartens G; Wasserman S; Shah NS; Farhat MR; Gandhi NR; Ismail N; Brust JCM; Mathema B
Clin Infect Dis; 2024 Feb; 78(2):269-276. PubMed ID: 37874928
[TBL] [Abstract][Full Text] [Related]
45. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
46. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China.
Yang J; Pang Y; Zhang T; Xian X; Li Y; Wang R; Wang P; Zhang M; Wang J
Int J Infect Dis; 2020 Oct; 99():163-170. PubMed ID: 32738481
[TBL] [Abstract][Full Text] [Related]
47. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
[TBL] [Abstract][Full Text] [Related]
48. Genetic variants and their association with phenotypic resistance to bedaquiline in
Ismail N; Rivière E; Limberis J; Huo S; Metcalfe JZ; Warren RM; Van Rie A
Lancet Microbe; 2021 Nov; 2(11):e604-e616. PubMed ID: 34796339
[TBL] [Abstract][Full Text] [Related]
49. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
Beckert P; Sanchez-Padilla E; Merker M; Dreyer V; Kohl TA; Utpatel C; Köser CU; Barilar I; Ismail N; Omar SV; Klopper M; Warren RM; Hoffmann H; Maphalala G; Ardizzoni E; de Jong BC; Kerschberger B; Schramm B; Andres S; Kranzer K; Maurer FP; Bonnet M; Niemann S
Genome Med; 2020 Nov; 12(1):104. PubMed ID: 33239092
[TBL] [Abstract][Full Text] [Related]
50. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
[TBL] [Abstract][Full Text] [Related]
51. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
Mok S; Roycroft E; Flanagan PR; Wagener J; Fitzgibbon MM
J Antimicrob Chemother; 2023 Nov; 78(11):2637-2644. PubMed ID: 37740935
[TBL] [Abstract][Full Text] [Related]
52. A review of tuberculosis: Focus on bedaquiline.
Chan B; Khadem TM; Brown J
Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
[TBL] [Abstract][Full Text] [Related]
53. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
Gras J
Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
[TBL] [Abstract][Full Text] [Related]
54. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
[TBL] [Abstract][Full Text] [Related]
55. Identification of genetic determinants of bedaquiline resistance in
Umpeleva T; Chetverikova E; Belyaev D; Eremeeva N; Boteva T; Golubeva L; Vakhrusheva D; Vasilieva I
Microbiol Spectr; 2024 Mar; 12(3):e0374923. PubMed ID: 38345388
[TBL] [Abstract][Full Text] [Related]
56. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
[TBL] [Abstract][Full Text] [Related]
57. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
[TBL] [Abstract][Full Text] [Related]
58. Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in
Guo Q; Bi J; Lin Q; Ye T; Wang Z; Wang Z; Liu L; Zhang G
Front Cell Infect Microbiol; 2022; 12():807095. PubMed ID: 35694543
[TBL] [Abstract][Full Text] [Related]
59. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.
Jang JC; Jung YG; Choi J; Jung H; Ryoo S
J Microbiol; 2017 Jun; 55(6):483-487. PubMed ID: 28429168
[TBL] [Abstract][Full Text] [Related]
60. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
